ERBB2 and breast carcinoma: MIM software has been used in a phase I study of 68 Ga-HER2-nanobody for PET/CT of HER2 Expression in breast carcinoma to analyze dosimetry and biodistribution [39] and neurological PET imaging by 18F-florbetapir uptake [40].